Containment Development Drug Delivery Systems FDA Approval 
Drug Discovery World
AUGUST 9, 2023
The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.
FDA Law Blog
MARCH 12, 2024
Failing to list the patents, as AstraZeneca points out, “may expose the reference drug sponsor to legal risks,” as “at least one generic applicant has argued that a failure to do so constitutes a violation of the antitrust laws by depriving the applicant of information that would have affected its decision whether to develop a generic product.”
Expert insights. Personalized for you.
52 
Let's personalize your content